Related Experiment Video
Updated: Aug 16, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10
Rama R Varma1, Suzanne M Hector, Kimberly Clark
1Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Abstract:
The efficacy of platinum drugs in the treatment of cancer is often restricted by the acquisition of tumor cell resistance subsequent to treatment. To better understand mechanisms involved in this phenomenon, a clonal subline (A2780/C10B) isolated from an oxaliplatin-resistant human ovarian carcinoma cell line (A2780/C10) was developed, as reported previously. This cell line is 18-fold resistant to oxaliplatin and shows a 3-fold cross resistance to cisplatin. Here, we report on the gene expression analysis using Affymetrix HG-U95Av2 oligonucleotide arrays of cells in log phase growth from both the parental cell line and drug-resistant variant. Probe level analysis was perfomed using the model based expression index (dChip) and robust multichip average (RMA) methods. Genes that were differentially expressed between the two groups were identified using the significance analysis of microarrays (SAM) method with a minimum false discovery rate <1%. We identified 43 genes that were overexpressed, and 39 underexpressed in the drug-resistant cell line. Collagen VI (COL6A3) was overexpressed 62-fold and the most highly up-regulated gene. This finding is consistent with other published data based on serial analysis of gene expression (SAGE) profiling of cisplatin-resistant and sensitive ovarian carcinoma cells. Among the significant functional groups of overexpressed genes in our study were extracellular matrix genes (9 of 43) and those involved in signal transduction (7 of 43). Extracellular matrix genes included two matrix metalloproteinases (MMP3 and MMP12). Integrin alpha 1 (ITGA1) and WNT5A were also overexpressed. Genes that encode for extracellular matrix proteins were also among those found down-regulated in the resistant cell line. Several genes involved in the regulation of cell cycle and growth were found to be underexpressed, including the suppressor of cytokine signaling 2 (SOCS2), necdin (NDN), and glypicans (GPC3 and GPC4). The mRNA levels of six differentially expressed genes (COL6A3, MMP12, MMP3, WNT5A, NID, and HMGB2) were validated using real-time quantitative RT-PCR. The identification of these genes should aid in a better understanding of the pathways resulting in platinum drug resistance.
Insights
This study identifies key genes, including Collagen VI (COL6A3), overexpressed in platinum-drug resistant ovarian cancer cells. Understanding these gene expression changes offers new insights into overcoming cancer treatment resistance.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Platinum-based chemotherapy is a cornerstone in ovarian cancer treatment.
- Tumor cell resistance to platinum drugs significantly limits treatment efficacy.
- Understanding the molecular mechanisms of drug resistance is crucial for developing effective therapeutic strategies.
Purpose of the Study:
- To identify differentially expressed genes in an oxaliplatin-resistant human ovarian carcinoma cell line compared to its sensitive parental line.
- To elucidate molecular pathways contributing to platinum drug resistance in ovarian cancer.
- To validate the expression levels of selected genes using quantitative real-time RT-PCR.
Main Methods:
- Gene expression profiling using Affymetrix HG-U95Av2 oligonucleotide arrays.
- Statistical analysis of gene expression data using dChip, RMA, and SAM methods.
- Validation of mRNA levels for key genes using real-time quantitative RT-PCR.
Main Results:
- Identified 43 overexpressed and 39 underexpressed genes in the drug-resistant cell line.
- Collagen VI (COL6A3) showed a 62-fold overexpression, being the most significantly upregulated gene.
- Overexpressed genes were enriched in extracellular matrix and signal transduction categories, including matrix metalloproteinases (MMP3, MMP12).
- Underexpressed genes included those involved in cell cycle and growth regulation, such as SOCS2, NDN, GPC3, and GPC4.
Conclusions:
- The study identified specific genes and pathways associated with platinum drug resistance in ovarian cancer.
- Upregulation of extracellular matrix genes like COL6A3 and MMPs, and downregulation of cell cycle regulators, are implicated in resistance.
- These findings provide a foundation for understanding platinum resistance mechanisms and developing targeted therapies.
More Related Videos
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
09:40Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024